Pre-Exposure Prophylaxis (PrEP) is a daily, oral medicine that prevents HIV infection. When taken as prescribed, it is over 90% effective and can serve as a primary preventative tool for those wanting to practice safer sex. Notably, it serves as a risk reduction tool for those at highest risk of acquiring HIV, including, men who have sex with men (MSM), transgender women, and sex workers.

Many resources exist to help guide healthcare providers in prescribing PrEP. The PrEP Action Kit below describes how to incorporate PrEP into your practice, including evaluation and monitoring strategies for particular communities at higher risk of HIV infection. Apply your new knowledge with the provided clinical cases, and learn more about medication risks by following the link to the REMS site. Currently, Truvada is the only FDA approved option for PrEP, though other medications are undergoing clinical trials and may be offered in the future.

- **PrEP Action Kit** by the National LGBT Health Education Center at The Fenway Institute
- **PrEP Clinical Case Applications** by the National LGBT Health Education Center at The Fenway Institute
- **Risk Evaluation & Mitigation Strategies** (REMS) for Truvada as PrEP

Many patients may have cost-prohibitive barriers to starting PrEP. It's important to advocate for the needs of these patients, and resources exist to expand access to those who are uninsured or those who do not have full insurance coverage for this medication. There are resources available to increase access for these patients:

- **Payment Assistance Programming** by Truvada for PrEP
- **Advancing Access** by Gilead

Interested in accessing more information quickly in clinic? If you have access to UpToDate, there is great data to guide patient evaluation, selection, and monitoring for PrEP.

Authors: Corey Walsh, BS & Cara Cheevers, MSW. Revised June 2019.